Stay updated on Platinum Therapy With TSR-042 & Niraparib in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Platinum Therapy With TSR-042 & Niraparib in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Platinum Therapy With TSR-042 & Niraparib in Ovarian Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page revision updated from v3.4.1 to v3.4.2; this appears to be a minor version update with no user-facing content changes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T12:36:22.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Added Primary peritoneal carcinoma to the Conditions and introduced a new Resources link to the Genetic and Rare Diseases Information Center. Page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-07T08:27:31.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    - Show glossary toggle added; - new study-record metadata appears (Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0), replacing older labels/versions. These changes affect UI labels and data disclosures but do not alter the core study details.
    Difference
    0.1%
    Check dated 2026-01-24T03:14:57.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    A new revision tag, Revision: v3.3.4, was added and the previous Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T01:28:52.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Results status updated to 'Results Posted' on 2025-12-31; enrollment is now listed as 1400 and the study sites expanded to 182 locations (including Kharkiv, Ukraine; Zaragoza, Spain; Kiel, Germany). The prior 'Results Submitted' entry and Maplewood, MN site (1402) were removed, and the changes include expanded outcome definitions and instrument details (PFS, OS, PFS2, TFST, TSST, ORR, DCR, ADAs, EQ-5D-5L and EORTC QLQ measures).
    Difference
    2%
    Check dated 2026-01-02T19:24:05.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Added a unified Locations section listing all study sites by state/province and country; older per-location lists were removed in favor of this consolidated presentation, with Revision: v3.3.3.
    Difference
    1%
    Check dated 2025-12-19T10:47:28.000Z thumbnail image

Stay in the know with updates to Platinum Therapy With TSR-042 & Niraparib in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Platinum Therapy With TSR-042 & Niraparib in Ovarian Cancer Clinical Trial page.